Stately Bio, a company developing cell therapies using an ML-based live-cell imaging platform, announced $12 million in seed funding led by AIX Ventures, with participation from Dimension Capital, ...

Researchers can easily track and isolate bit.bio's consistent, defined, and scalable human iPSC-derived cells for the first time, opening up new applications in neurodegenerative drug discovery.

Generation Bio announces new programs using ctLNP for targeted siRNA delivery in T cell-driven autoimmune diseases, aiming for IND submission in 2026. Development of novel siRNA therapeutics using ...